Valneva SE ("Valneva" or "the Company"), a fully
integrated, commercial stage biotech company focused on developing
innovative, life-saving vaccines, announces today the signing of a
$39.6 million one year contract with the US Government's Department
of Defense for the supply of its Japanese encephalitis (JE) vaccine
IXIARO®. The new agreement will supplement the initial contract
Valneva signed with the US military in March 2016 as the maximum
quantity of doses allowed in the precedent contract was reached
earlier than expected.
Under the terms of the new agreement, Valneva will supply the
IXIARO®doses to the Defense Logistics Agency (DLA), Supply Center
of the US Department of Defense, over a one-year period for a value
of $28.2 million guaranteed and up to $39.6 million. First
deliveries are expected to commence in the coming weeks.
The increase in the US military demand follows an update of the
US Navy medical guidance at the end of 2016 which made JE
vaccination compulsory for all Navy personnel and DoD employees
assigned to Japan or the Korean peninsula for over 30 days. At the
time of this update, vaccination against Japanese encephalitis was
already required for U.S Air Force personnel, US Army, and the
Marine Corps so assigned.
Franck Grimaud, President and CBO of Valneva
commented, "The US military has been using
IXIARO® since 2010 and it has now become an established
vaccine to protect the military personnel and their families
stationed in Asia. We are extremely pleased to see that its usage
is expanding, notably with the latest addition of the US Navy, and
look forward to continuing working with the US government to fight
this deadly disease."
IXIARO® is the only JE vaccine approved in the US. Valneva,
which successfully established its own global marketing &
distribution network in 2015, now markets and distributes
IXIARO® directly to the US military.
About IXIARO®/JESPECT®
Valneva's Japanese encephalitis vaccine is indicated for active
immunization for the prevention of Japanese encephalitis for adults
who travel to, or live in, endemic areas. It has received marketing
approval in the U.S., Europe, Canada, Hong Kong, Singapore, and
Israel under the trade name IXIARO®and in Australia and New Zealand
where it is marketed as JESPECT®. It is the only vaccine being
marketed to the U.S. military for Japanese encephalitis.
IXIARO® is approved for use in individuals 2 months of age and
older in the US and EU member states, Norway, Liechtenstein,
Iceland, Singapore, Hong Kong and Israel. In all other licensed
territories, IXIARO®/JESPECT® is indicated for use in persons
18 years of age and above.
About Japanese Encephalitis
Japanese Encephalitis (JE) is a deadly infectious disease found
mainly in Asia. About 70,000 cases of JE are estimated to occur in
Asia each year, although the actual number of cases is likely much
higher due to underreporting in rural areas. JE is fatal in
approximately 30 percent of those who show symptoms, and leaves
half of survivors with permanent brain damage. The disease is
endemic in Southeast Asia, India and China, a region with more than
3 billion inhabitants. In 2005, Japanese encephalitis killed more
than 1,200 children in only one month during an epidemic outbreak
in Uttar Pradesh, India, and Nepal.
About Valneva SE
Valneva is a fully integrated, commercial stage biotech company
focused on developing innovative life-saving vaccines.
Valneva's portfolio includes two commercial vaccines for
travelers: IXIARO®/JESPECT® indicated for the prevention of
Japanese encephalitis and DUKORAL® indicated for the
prevention of cholera and, in some countries, prevention of
diarrhea caused by ETEC. The Company has proprietary vaccines in
development including a unique vaccine against Lyme disease. A
variety of partnerships with leading pharmaceutical companies
complement the Company's value proposition and include vaccines
being developed using Valneva's innovative and validated technology
platforms (EB66® cell line and IC31® adjuvant).
Valneva shares are tradable on Euronext-Paris, the Vienna stock
exchange and Deutsche Börse's electronic platform Xetra®. The
Company has operations in France, Austria, Great Britain, Sweden,
Canada and the US with over 400 employees. More information is
available at www.valneva.com.
Valneva
Investor and Media Contacts Laetitia Bachelot Fontaine
Global Head of Investor Relations & Corporate
Communications T +33 (0)2 2807 1419 M +33 (0)6 4516 7099
investors@valneva.com |
Nina Waibel
Corporate Communications Specialist T +43 1206 201 149 M +43
6768 455 6719 Communications@valneva.com |
Forward-Looking Statements
This press release contains certain forward-looking statements
relating to the business of Valneva, including with respect to the
progress, timing and completion of research, development and
clinical trials for product candidates, the ability to
manufacture, market, commercialize and achieve market acceptance
for product candidates, the ability to protect intellectual
property and operate the business without infringing on the
intellectual property rights of others, estimates for future
performance and estimates regarding anticipated operating losses,
future revenues, capital requirements and needs for additional
financing. In addition, even if the actual results or development
of Valneva are consistent with the forward-looking statements
contained in this press release, those results or developments of
Valneva may not be indicative of their in the future. In some
cases, you can identify forward-looking statements by words such as
"could," "should," "may," "expects," "anticipates," "believes,"
"intends," "estimates," "aims," "targets," or similar words. These
forward-looking statements are based largely on the current
expectations of Valneva as of the date of this press release and
are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievement expressed or implied by
these forward-looking statements. In particular, the expectations
of Valneva could be affected by, among other things, uncertainties
involved in the development and manufacture of vaccines, unexpected
clinical trial results, unexpected regulatory actions or delays,
competition in general, currency fluctuations, the impact of the
global and European credit crisis, and the ability to obtain or
maintain patent or other proprietary intellectual property
protection. In light of these risks and uncertainties, there can be
no assurance that the forward-looking statements made during this
presentation will in fact be realized. Valneva is providing the
information in these materials as of this press release, and
disclaim any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise.